Start-Up Quarterly Statistics, Q1 2010
This article was originally published in Start Up
Executive Summary
Highlights from the Q1 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $331 million, a 66% drop from the previous quarter's $976 million, and a 52% slide from Q1 2009. As was the case in Q4 2009, Series B rounds dominated in the biopharma and device sectors. Just one acquisition closed in the quarter - BioMarin buying LEAD Therapeutics - however two others are in the works. On the alliance front, SpePharm and Dicerna each signed two deals in Q1.
You may also be interested in...
J&J/Ethicon Endo-Surgery Weighs Breast Care Divestiture To Devicor
Devicor Medical Products is seeking a foothold in the device market with its proposed acquisition of Johnson & Johnson/Ethicon Endo-Surgery's breast care business, the company announced March 30
GSK Doubles Up With Regulus, Signing New Collaboration For HCV Therapeutics
Second collaboration with GSK could bring the microRNA-focused biotech more than $150 million in upfront and milestone payments.
Venture-Backed Dicerna Cuts First Pharma Deal With Kyowa Hakko Kirin As Prelude to 'B' Round
As it looks for a new investor to lead its second round of funding, RNA interference start-up Dicerna Pharmaceuticals has signed its first big-pharma customer. Japan's Kyowa Hakko Kirin will pay $4 million up-front and as much as $120 million in milestones to develop therapeutics around an undisclosed solid-tumor cancer target using Dicerna's technology